Whey-derived peptides at the heart of the COVID-19 pandemic

[thumbnail of Open Access]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.
| Preview
Available under license: Creative Commons Attribution
[thumbnail of Chamata et al_Revised manuscript_ACCEPTED VERSION.docx]
Text - Accepted Version
· Restricted to Repository staff only
Restricted to Repository staff only

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Chamata, Y., Jackson, K. G. orcid id iconORCID: https://orcid.org/0000-0002-0070-3203, Watson, K. A. orcid id iconORCID: https://orcid.org/0000-0002-9987-8539 and Jauregi, P. (2021) Whey-derived peptides at the heart of the COVID-19 pandemic. International Journal of Molecular Sciences, 22 (21). 11662. ISSN 1422-0067 doi: 10.3390/ijms222111662

Abstract/Summary

The renin–angiotensin system (RAS) is a key regulator of blood pressure and hypertension. An-giotensin converting enzyme 2 (ACE2) and angiotensin converting enzyme I (ACE) are two main components of the RAS that play a major role in blood pressure homeostasis. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses ACE2 as a receptor to enter the cells. Despite some controversies, numerous studies have reported a significant association be-tween the use of ACE inhibitors, and reduced risk of COVID-19. In our previous studies, we pro-duced and identified peptide sequences present in whey hydrolysates exhibiting high ACE in-hibitory activity. Therefore, the aim of this work is to obtain an improved understanding of the function of these natural peptides as RAS inhibitors and investigate their potential therapeutic role in the COVID-19 pandemic. The molecular interactions between peptides IPP, LIVTQ, IIAE, LVYPFP, and human ACE2 were assessed employing a molecular docking approach. The results show that natural whey-derived peptides have a dual inhibitory action against both ACE and ACE2. This dual activity distinguishes these ACE inhibitory peptides from synthetic drugs, such as Captopril and Lisinopril that were not shown to inhibit ACE2 activity, and may represent a potential strategy in the treatment of COVID-19.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/101254
Identification Number/DOI 10.3390/ijms222111662
Refereed Yes
Divisions Interdisciplinary centres and themes > Institute for Cardiovascular and Metabolic Research (ICMR)
Life Sciences > School of Biological Sciences > Biomedical Sciences
Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Human Nutrition Research Group
Life Sciences > School of Chemistry, Food and Pharmacy > Department of Food and Nutritional Sciences > Food Research Group
Publisher MDPI
Download/View statistics View download statistics for this item

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar